Oramed Enrolls First Patient in its Phase 2a U.S. Oral Insulin Clinical Trial

New Drug Approvals

Nadav Kidron

Marks initiation of Oramed’s first FDA trial for its flagship ORMD-0801 oral insulin product

JERUSALEM, July 8, 2013

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the first patient has been enrolled in a Phase 2a trial of ORMD-0801, an orally ingestible insulin capsule, on patients with type 2 diabetes. The current trial is to be a randomized, double-blind study designed to assess the safety of ORMD-0801.
Read more at

http://www.drugs.com/clinical_trials/oramed-enrolls-first-patient-phase-2a-u-s-oral-insulin-clinical-trial-15855.html

In addition to ORMD-0801, Oramed is also developing an oral GLP-1 analog, known as exenatide, and a combination therapy of ORMD-0801 and exenatide.
GLP-1, or glucagon-like peptide-1, possesses a number of physiological properties that make it and its analogs the subject of intensive investigation as a potential treatment for diabetes. Among other things, it aids in the balance of blood sugar levels by decreasing glucose levels, especially…

View original post 11 more words

Advertisements